CHRM1 is a Druggable Melanoma Target Whose Endogenous Activity is Determined by Inherited Genetic Variation in DOPA Production
Miriam Doepner(University of Pennsylvania)
Cited by 0
Related Papers
Endogenous DOPA inhibits melanoma through suppression of CHRM1 signaling
|Science Advances|2022|24